| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 208 | 2024 | 5706 | 14.010 |
Why?
|
| Antibodies, Monoclonal | 99 | 2023 | 9180 | 5.370 |
Why?
|
| Skin Neoplasms | 81 | 2024 | 5820 | 4.920 |
Why?
|
| Immunotherapy | 68 | 2023 | 4649 | 3.860 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 63 | 2024 | 11735 | 3.510 |
Why?
|
| Antineoplastic Agents | 64 | 2023 | 13635 | 2.580 |
Why?
|
| Cancer Vaccines | 25 | 2023 | 1050 | 2.530 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 17 | 2023 | 892 | 2.440 |
Why?
|
| Neoplasms | 70 | 2024 | 22158 | 2.120 |
Why?
|
| Uveal Neoplasms | 8 | 2024 | 341 | 1.970 |
Why?
|
| Mucous Membrane | 9 | 2021 | 657 | 1.660 |
Why?
|
| Proto-Oncogene Proteins c-kit | 9 | 2017 | 728 | 1.640 |
Why?
|
| Proto-Oncogene Proteins B-raf | 24 | 2021 | 2052 | 1.620 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 18 | 2020 | 1089 | 1.410 |
Why?
|
| CD8-Positive T-Lymphocytes | 20 | 2024 | 4576 | 1.360 |
Why?
|
| Indoles | 11 | 2019 | 1832 | 1.200 |
Why?
|
| Tumor Microenvironment | 22 | 2024 | 3873 | 1.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 9 | 2024 | 3489 | 1.170 |
Why?
|
| Immunomodulation | 5 | 2019 | 547 | 1.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 21 | 2024 | 5303 | 1.110 |
Why?
|
| Maximum Tolerated Dose | 11 | 2024 | 883 | 1.070 |
Why?
|
| Antigens, CD | 13 | 2022 | 4000 | 1.030 |
Why?
|
| Oncolytic Viruses | 3 | 2021 | 344 | 1.000 |
Why?
|
| Neoplasm Metastasis | 32 | 2024 | 4908 | 0.980 |
Why?
|
| Pneumonia | 8 | 2021 | 2140 | 0.970 |
Why?
|
| Mutation | 38 | 2023 | 30044 | 0.960 |
Why?
|
| Humans | 346 | 2024 | 761326 | 0.950 |
Why?
|
| Pyrimidines | 6 | 2017 | 3025 | 0.950 |
Why?
|
| Lung Neoplasms | 27 | 2024 | 13333 | 0.870 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2018 | 425 | 0.860 |
Why?
|
| T-Lymphocytes, Cytotoxic | 7 | 2019 | 1783 | 0.850 |
Why?
|
| Aged | 139 | 2024 | 169179 | 0.820 |
Why?
|
| Middle Aged | 157 | 2024 | 220774 | 0.820 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2024 | 664 | 0.810 |
Why?
|
| Drug Resistance, Neoplasm | 14 | 2024 | 5297 | 0.810 |
Why?
|
| Neoplasm Staging | 45 | 2022 | 11098 | 0.800 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2020 | 3161 | 0.790 |
Why?
|
| Aged, 80 and over | 70 | 2024 | 58946 | 0.750 |
Why?
|
| Disease-Free Survival | 28 | 2019 | 6815 | 0.740 |
Why?
|
| Pyrroles | 4 | 2024 | 1126 | 0.730 |
Why?
|
| Brain Neoplasms | 18 | 2021 | 9030 | 0.720 |
Why?
|
| Triazoles | 2 | 2018 | 903 | 0.720 |
Why?
|
| Treatment Outcome | 71 | 2024 | 64645 | 0.700 |
Why?
|
| Protein Kinase Inhibitors | 15 | 2024 | 5665 | 0.700 |
Why?
|
| Protein Kinase C | 3 | 2020 | 1202 | 0.690 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2019 | 6473 | 0.690 |
Why?
|
| Antibodies, Neoplasm | 4 | 2016 | 281 | 0.690 |
Why?
|
| Oncolytic Virotherapy | 4 | 2022 | 516 | 0.670 |
Why?
|
| Antigens, Differentiation | 4 | 2008 | 910 | 0.660 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2019 | 61 | 0.660 |
Why?
|
| Male | 167 | 2024 | 360621 | 0.660 |
Why?
|
| Female | 175 | 2024 | 392485 | 0.650 |
Why?
|
| Drug Administration Schedule | 18 | 2024 | 4850 | 0.630 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 4371 | 0.630 |
Why?
|
| Granuloma | 2 | 2018 | 327 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2021 | 8527 | 0.610 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 2 | 2014 | 195 | 0.610 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2018 | 45 | 0.600 |
Why?
|
| Antibodies, Blocking | 4 | 2019 | 243 | 0.590 |
Why?
|
| Antigens, Neoplasm | 14 | 2021 | 1994 | 0.580 |
Why?
|
| Clinical Trials as Topic | 22 | 2023 | 7999 | 0.570 |
Why?
|
| Lymphoma | 5 | 2022 | 1901 | 0.570 |
Why?
|
| Adult | 113 | 2024 | 221122 | 0.570 |
Why?
|
| Piperazines | 4 | 2014 | 2519 | 0.560 |
Why?
|
| Angiopoietin-2 | 2 | 2016 | 172 | 0.540 |
Why?
|
| Molecular Targeted Therapy | 14 | 2021 | 2811 | 0.530 |
Why?
|
| Galectin 1 | 1 | 2017 | 128 | 0.530 |
Why?
|
| Leukocytes, Mononuclear | 10 | 2024 | 1842 | 0.520 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2021 | 774 | 0.520 |
Why?
|
| Colitis | 7 | 2022 | 1231 | 0.520 |
Why?
|
| Herpesvirus 1, Human | 3 | 2022 | 753 | 0.510 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 825 | 0.500 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 3734 | 0.490 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 4 | 2021 | 641 | 0.480 |
Why?
|
| GTP-Binding Protein alpha Subunits | 2 | 2012 | 102 | 0.480 |
Why?
|
| Dose-Response Relationship, Drug | 20 | 2024 | 10764 | 0.480 |
Why?
|
| Sulfonamides | 7 | 2014 | 1976 | 0.480 |
Why?
|
| Benzamides | 4 | 2014 | 1370 | 0.470 |
Why?
|
| Combined Modality Therapy | 13 | 2022 | 8526 | 0.470 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 273 | 0.470 |
Why?
|
| Neovascularization, Pathologic | 5 | 2019 | 2644 | 0.470 |
Why?
|
| Killer Cells, Natural | 4 | 2023 | 2203 | 0.460 |
Why?
|
| Survival Rate | 22 | 2021 | 12710 | 0.450 |
Why?
|
| Kidney Neoplasms | 10 | 2020 | 4246 | 0.450 |
Why?
|
| Hydroxamic Acids | 1 | 2016 | 481 | 0.440 |
Why?
|
| HLA Antigens | 2 | 2018 | 1371 | 0.440 |
Why?
|
| Drug Synergism | 3 | 2016 | 1757 | 0.440 |
Why?
|
| MAP Kinase Kinase Kinases | 5 | 2019 | 255 | 0.440 |
Why?
|
| Clinical Trials, Phase II as Topic | 8 | 2019 | 628 | 0.430 |
Why?
|
| T-Lymphocytes | 15 | 2023 | 10191 | 0.430 |
Why?
|
| Inhibitor of Apoptosis Proteins | 4 | 2016 | 197 | 0.430 |
Why?
|
| Radiotherapy | 2 | 2019 | 1499 | 0.420 |
Why?
|
| Disease Progression | 23 | 2022 | 13500 | 0.420 |
Why?
|
| Prognosis | 29 | 2021 | 29588 | 0.400 |
Why?
|
| Immunity, Humoral | 5 | 2019 | 605 | 0.400 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2020 | 3075 | 0.400 |
Why?
|
| Cell Line, Tumor | 23 | 2020 | 16966 | 0.400 |
Why?
|
| Immunity, Cellular | 3 | 2016 | 1560 | 0.390 |
Why?
|
| Neoplasm Proteins | 8 | 2021 | 3611 | 0.390 |
Why?
|
| Ovarian Neoplasms | 5 | 2020 | 4877 | 0.390 |
Why?
|
| Sunlight | 1 | 2013 | 337 | 0.380 |
Why?
|
| Hepatitis | 3 | 2023 | 229 | 0.370 |
Why?
|
| Thyroid Diseases | 3 | 2019 | 386 | 0.370 |
Why?
|
| Immunophenotyping | 7 | 2022 | 1870 | 0.370 |
Why?
|
| Cell Proliferation | 9 | 2021 | 10431 | 0.360 |
Why?
|
| Quinazolines | 2 | 2020 | 1371 | 0.360 |
Why?
|
| Cytokines | 11 | 2022 | 7390 | 0.330 |
Why?
|
| Melanoma, Experimental | 4 | 2019 | 560 | 0.330 |
Why?
|
| Peptide Fragments | 3 | 2019 | 5114 | 0.330 |
Why?
|
| Apoptosis | 8 | 2021 | 9474 | 0.320 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2019 | 1805 | 0.320 |
Why?
|
| Medical Oncology | 4 | 2023 | 2321 | 0.320 |
Why?
|
| Tumor Burden | 8 | 2022 | 1887 | 0.310 |
Why?
|
| Gene Amplification | 1 | 2013 | 1086 | 0.310 |
Why?
|
| Antibody Formation | 5 | 2016 | 1397 | 0.310 |
Why?
|
| Survival Analysis | 15 | 2020 | 10075 | 0.310 |
Why?
|
| Imidazoles | 6 | 2019 | 1179 | 0.310 |
Why?
|
| Tumor Escape | 3 | 2021 | 370 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2012 | 570 | 0.300 |
Why?
|
| MAP Kinase Signaling System | 2 | 2012 | 1486 | 0.300 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 3531 | 0.290 |
Why?
|
| Double-Blind Method | 11 | 2022 | 12329 | 0.280 |
Why?
|
| Autoimmunity | 3 | 2018 | 1355 | 0.270 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2021 | 1875 | 0.270 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2019 | 20555 | 0.270 |
Why?
|
| Amino Acid Sequence | 4 | 2021 | 13446 | 0.270 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2013 | 614 | 0.270 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2023 | 5670 | 0.270 |
Why?
|
| Tumor Cells, Cultured | 9 | 2021 | 6128 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 2 | 2024 | 1959 | 0.260 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 39108 | 0.260 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 1896 | 0.260 |
Why?
|
| Oximes | 4 | 2019 | 303 | 0.260 |
Why?
|
| Clinical Trials, Phase III as Topic | 7 | 2018 | 857 | 0.260 |
Why?
|
| Adjuvants, Immunologic | 3 | 2022 | 1036 | 0.250 |
Why?
|
| Immunization, Passive | 1 | 2008 | 616 | 0.250 |
Why?
|
| Endocrine System Diseases | 2 | 2018 | 249 | 0.250 |
Why?
|
| Cell Adhesion Molecules | 2 | 2023 | 1600 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 2859 | 0.240 |
Why?
|
| Gene Expression Profiling | 13 | 2021 | 9414 | 0.240 |
Why?
|
| Rectal Neoplasms | 2 | 2016 | 1157 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2022 | 9275 | 0.230 |
Why?
|
| Ploidies | 1 | 2024 | 284 | 0.230 |
Why?
|
| North America | 2 | 2021 | 1275 | 0.230 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 1931 | 0.230 |
Why?
|
| Animals | 47 | 2024 | 168388 | 0.230 |
Why?
|
| Autoantigens | 1 | 2008 | 892 | 0.230 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1589 | 0.220 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2023 | 1351 | 0.220 |
Why?
|
| NF-kappa B | 1 | 2012 | 2488 | 0.220 |
Why?
|
| Immunohistochemistry | 12 | 2019 | 11070 | 0.220 |
Why?
|
| Hypothyroidism | 3 | 2019 | 667 | 0.220 |
Why?
|
| Young Adult | 25 | 2021 | 59196 | 0.220 |
Why?
|
| Immunosuppressive Agents | 4 | 2021 | 4173 | 0.210 |
Why?
|
| Retrospective Studies | 36 | 2024 | 80575 | 0.210 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2011 | 2897 | 0.210 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2021 | 365 | 0.210 |
Why?
|
| Lymphocytes | 4 | 2020 | 2610 | 0.210 |
Why?
|
| Alanine Transaminase | 2 | 2024 | 605 | 0.210 |
Why?
|
| Tobacco, Smokeless | 1 | 2023 | 133 | 0.210 |
Why?
|
| Urologic Neoplasms | 2 | 2018 | 313 | 0.200 |
Why?
|
| Flow Cytometry | 7 | 2023 | 5866 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2022 | 781 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2023 | 3613 | 0.200 |
Why?
|
| Immune Tolerance | 3 | 2011 | 2300 | 0.200 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2018 | 326 | 0.200 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2021 | 68 | 0.200 |
Why?
|
| SOXE Transcription Factors | 1 | 2021 | 73 | 0.190 |
Why?
|
| Carcinoma | 2 | 2016 | 2328 | 0.190 |
Why?
|
| Up-Regulation | 2 | 2024 | 4120 | 0.190 |
Why?
|
| Thyrotoxicosis | 2 | 2019 | 85 | 0.190 |
Why?
|
| Enterocolitis | 1 | 2022 | 106 | 0.190 |
Why?
|
| Lymphadenitis | 1 | 2022 | 99 | 0.190 |
Why?
|
| Leukoplakia, Oral | 1 | 2021 | 77 | 0.190 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 2 | 2012 | 147 | 0.190 |
Why?
|
| Cohort Studies | 18 | 2021 | 41440 | 0.190 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2021 | 1355 | 0.180 |
Why?
|
| Epitopes | 4 | 2021 | 2504 | 0.180 |
Why?
|
| Gastritis | 1 | 2022 | 199 | 0.180 |
Why?
|
| Histiocytes | 1 | 2021 | 98 | 0.180 |
Why?
|
| Injections, Intralesional | 1 | 2021 | 277 | 0.180 |
Why?
|
| Monitoring, Immunologic | 1 | 2021 | 98 | 0.180 |
Why?
|
| Splenic Neoplasms | 1 | 2021 | 94 | 0.180 |
Why?
|
| Recombinant Proteins | 7 | 2018 | 6525 | 0.180 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 174 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1405 | 0.180 |
Why?
|
| Primary Myelofibrosis | 1 | 2022 | 209 | 0.180 |
Why?
|
| Methylprednisolone | 1 | 2021 | 384 | 0.170 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 262 | 0.170 |
Why?
|
| Pyrimidinones | 4 | 2019 | 385 | 0.170 |
Why?
|
| Immune System Diseases | 1 | 2022 | 257 | 0.170 |
Why?
|
| Microvessels | 1 | 2024 | 575 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 2 | 2013 | 516 | 0.170 |
Why?
|
| Endogenous Retroviruses | 1 | 2020 | 111 | 0.170 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2012 | 716 | 0.170 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2021 | 178 | 0.170 |
Why?
|
| Colitis, Microscopic | 1 | 2020 | 72 | 0.160 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2019 | 123 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 4022 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 1069 | 0.160 |
Why?
|
| Addison Disease | 1 | 2019 | 48 | 0.160 |
Why?
|
| Microsatellite Repeats | 2 | 2018 | 785 | 0.160 |
Why?
|
| Drug Monitoring | 3 | 2021 | 961 | 0.160 |
Why?
|
| Time Factors | 15 | 2021 | 39974 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2021 | 10203 | 0.150 |
Why?
|
| Myeloid Cells | 2 | 2020 | 823 | 0.150 |
Why?
|
| Enzyme Activation | 3 | 2015 | 3592 | 0.150 |
Why?
|
| Pruritus | 2 | 2019 | 380 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 117 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2021 | 196 | 0.150 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2020 | 1469 | 0.150 |
Why?
|
| Pancreatitis | 2 | 2023 | 1096 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 696 | 0.150 |
Why?
|
| Membrane Glycoproteins | 4 | 2016 | 3701 | 0.150 |
Why?
|
| Lymphocyte Activation | 4 | 2019 | 5491 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
| Reed-Sternberg Cells | 1 | 2017 | 72 | 0.150 |
Why?
|
| Bone Marrow Cells | 3 | 2022 | 2416 | 0.140 |
Why?
|
| Colonic Neoplasms | 2 | 2022 | 2534 | 0.140 |
Why?
|
| Retreatment | 2 | 2016 | 598 | 0.140 |
Why?
|
| Melanoma-Specific Antigens | 2 | 2018 | 74 | 0.140 |
Why?
|
| Isoenzymes | 2 | 2012 | 1688 | 0.140 |
Why?
|
| Antigens, CD19 | 1 | 2020 | 425 | 0.140 |
Why?
|
| Pyridones | 4 | 2019 | 808 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2021 | 2549 | 0.140 |
Why?
|
| Cell Separation | 3 | 2018 | 1722 | 0.140 |
Why?
|
| Receptors, Chemokine | 1 | 2020 | 653 | 0.140 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 29 | 0.140 |
Why?
|
| Skin | 3 | 2019 | 4482 | 0.140 |
Why?
|
| Mice | 24 | 2024 | 81474 | 0.140 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 640 | 0.140 |
Why?
|
| Radiotherapy Dosage | 2 | 2022 | 2898 | 0.140 |
Why?
|
| Fatigue | 3 | 2019 | 1551 | 0.140 |
Why?
|
| Cryopreservation | 1 | 2022 | 728 | 0.140 |
Why?
|
| Signal Transduction | 5 | 2019 | 23427 | 0.140 |
Why?
|
| Interferon-gamma | 4 | 2020 | 3159 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 5 | 2017 | 3588 | 0.140 |
Why?
|
| Lymphopenia | 1 | 2018 | 280 | 0.130 |
Why?
|
| Chemokines | 2 | 2020 | 960 | 0.130 |
Why?
|
| Dacarbazine | 2 | 2017 | 559 | 0.130 |
Why?
|
| Calcifediol | 1 | 2017 | 161 | 0.130 |
Why?
|
| Creatinine | 2 | 2019 | 1899 | 0.130 |
Why?
|
| Angiotensin II | 1 | 2019 | 849 | 0.130 |
Why?
|
| Histiocytosis, Sinus | 1 | 2016 | 45 | 0.130 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 311 | 0.130 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 1 | 2016 | 27 | 0.130 |
Why?
|
| Staining and Labeling | 4 | 2022 | 1085 | 0.130 |
Why?
|
| Genomics | 6 | 2024 | 5817 | 0.130 |
Why?
|
| Quality Control | 1 | 2018 | 835 | 0.130 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2008 | 101 | 0.130 |
Why?
|
| Genes, cdc | 1 | 2016 | 114 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2018 | 347 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2020 | 1114 | 0.130 |
Why?
|
| Cell Movement | 4 | 2016 | 5202 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2003 | 954 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 316 | 0.120 |
Why?
|
| Janus Kinase 3 | 1 | 2015 | 76 | 0.120 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 43 | 0.120 |
Why?
|
| Niacinamide | 2 | 2015 | 413 | 0.120 |
Why?
|
| Nephritis, Interstitial | 1 | 2016 | 155 | 0.120 |
Why?
|
| Bone Marrow | 2 | 2022 | 2909 | 0.120 |
Why?
|
| Endpoint Determination | 1 | 2018 | 590 | 0.120 |
Why?
|
| Single-Cell Analysis | 3 | 2021 | 2448 | 0.120 |
Why?
|
| Cell Survival | 3 | 2018 | 5792 | 0.120 |
Why?
|
| Central Nervous System | 2 | 2015 | 1337 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2018 | 559 | 0.120 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2016 | 123 | 0.120 |
Why?
|
| Chemokine CX3CL1 | 1 | 2014 | 63 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 72 | 0.120 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 1481 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2020 | 934 | 0.120 |
Why?
|
| Prednisone | 1 | 2019 | 1564 | 0.120 |
Why?
|
| Oxidoreductases | 1 | 2016 | 412 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2016 | 169 | 0.120 |
Why?
|
| Endothelial Cells | 2 | 2024 | 3543 | 0.110 |
Why?
|
| Fever | 2 | 2019 | 1618 | 0.110 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 529 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1051 | 0.110 |
Why?
|
| Exons | 2 | 2017 | 2392 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 3 | 2022 | 964 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2016 | 691 | 0.110 |
Why?
|
| Drug Evaluation | 1 | 2015 | 642 | 0.110 |
Why?
|
| Pituitary Diseases | 1 | 2014 | 135 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2016 | 262 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2509 | 0.110 |
Why?
|
| Protein Isoforms | 2 | 2017 | 1698 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2013 | 2453 | 0.110 |
Why?
|
| Lymphocyte Count | 4 | 2018 | 778 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 1742 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 322 | 0.110 |
Why?
|
| Immunotherapy, Active | 2 | 2010 | 59 | 0.110 |
Why?
|
| Interferon-alpha | 4 | 2022 | 921 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 263 | 0.110 |
Why?
|
| HLA-A2 Antigen | 2 | 2011 | 211 | 0.110 |
Why?
|
| Neutrophil Infiltration | 1 | 2016 | 387 | 0.110 |
Why?
|
| Encephalitis | 1 | 2017 | 438 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 1647 | 0.110 |
Why?
|
| Immediate-Early Proteins | 1 | 2016 | 449 | 0.110 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 6309 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 2017 | 422 | 0.110 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1640 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 2193 | 0.110 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2015 | 783 | 0.110 |
Why?
|
| Biological Specimen Banks | 1 | 2018 | 783 | 0.110 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 1394 | 0.110 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1858 | 0.100 |
Why?
|
| Lymphocyte Transfusion | 1 | 2013 | 232 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 4108 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2015 | 3806 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 1125 | 0.100 |
Why?
|
| Drug Eruptions | 2 | 2014 | 335 | 0.100 |
Why?
|
| Adolescent | 14 | 2021 | 88305 | 0.100 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 1303 | 0.100 |
Why?
|
| Carboplatin | 4 | 2018 | 794 | 0.100 |
Why?
|
| Intestine, Small | 1 | 2018 | 1205 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2012 | 203 | 0.100 |
Why?
|
| Quality of Life | 3 | 2022 | 13355 | 0.100 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 152 | 0.100 |
Why?
|
| Diarrhea | 4 | 2023 | 1319 | 0.100 |
Why?
|
| Eye Neoplasms | 1 | 2014 | 307 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2019 | 2047 | 0.100 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 642 | 0.100 |
Why?
|
| Models, Biological | 3 | 2013 | 9468 | 0.100 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 465 | 0.100 |
Why?
|
| Keratoacanthoma | 1 | 2012 | 33 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2012 | 285 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2013 | 602 | 0.100 |
Why?
|
| Smoking Cessation | 1 | 2023 | 2056 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 2853 | 0.100 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 609 | 0.100 |
Why?
|
| Research Design | 3 | 2019 | 6178 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 736 | 0.100 |
Why?
|
| Bromodeoxyuridine | 1 | 2012 | 311 | 0.100 |
Why?
|
| Phosphorylation | 2 | 2013 | 8312 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 946 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2020 | 2909 | 0.090 |
Why?
|
| Interleukin-2 | 4 | 2017 | 1891 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 319 | 0.090 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 725 | 0.090 |
Why?
|
| Stromal Cells | 1 | 2016 | 1330 | 0.090 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 473 | 0.090 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 378 | 0.090 |
Why?
|
| Colorectal Neoplasms | 3 | 2021 | 6901 | 0.090 |
Why?
|
| Sarcoidosis | 1 | 2016 | 521 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2016 | 807 | 0.090 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 1886 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2022 | 2210 | 0.090 |
Why?
|
| Cyclin D1 | 1 | 2012 | 451 | 0.090 |
Why?
|
| Biopsy | 4 | 2019 | 6768 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2016 | 3089 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 7389 | 0.080 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 1378 | 0.080 |
Why?
|
| ras Proteins | 1 | 2015 | 1053 | 0.080 |
Why?
|
| Patient Selection | 2 | 2021 | 4244 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2013 | 1647 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 3030 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2015 | 2009 | 0.080 |
Why?
|
| Cells, Cultured | 2 | 2019 | 18962 | 0.080 |
Why?
|
| Cell Membrane | 2 | 2015 | 3687 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2017 | 1394 | 0.080 |
Why?
|
| Viral Proteins | 1 | 2016 | 1803 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2013 | 685 | 0.080 |
Why?
|
| Clinical Protocols | 1 | 2014 | 1440 | 0.080 |
Why?
|
| Immunologic Memory | 2 | 2015 | 1359 | 0.080 |
Why?
|
| Stem Cells | 1 | 2021 | 3521 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 7 | 2021 | 22154 | 0.080 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 870 | 0.080 |
Why?
|
| Uterine Neoplasms | 1 | 2017 | 1420 | 0.080 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 84 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2018 | 3060 | 0.070 |
Why?
|
| Receptors, Immunologic | 3 | 2023 | 1412 | 0.070 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 801 | 0.070 |
Why?
|
| Endocrine Glands | 2 | 2018 | 102 | 0.070 |
Why?
|
| Immune System | 1 | 2013 | 794 | 0.070 |
Why?
|
| Proportional Hazards Models | 5 | 2021 | 12450 | 0.070 |
Why?
|
| Pyridines | 2 | 2017 | 2870 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 1385 | 0.070 |
Why?
|
| Gene Expression | 3 | 2019 | 7582 | 0.070 |
Why?
|
| Antibodies | 3 | 2020 | 2421 | 0.070 |
Why?
|
| Autoantibodies | 2 | 2008 | 2123 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 916 | 0.070 |
Why?
|
| Pathology | 1 | 2009 | 270 | 0.070 |
Why?
|
| Gastroenteritis | 1 | 2008 | 236 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1665 | 0.070 |
Why?
|
| Vitamin D | 1 | 2020 | 3304 | 0.070 |
Why?
|
| Positron-Emission Tomography | 4 | 2015 | 6478 | 0.070 |
Why?
|
| Disease Management | 4 | 2021 | 2504 | 0.070 |
Why?
|
| Protein Array Analysis | 1 | 2008 | 400 | 0.070 |
Why?
|
| Melanocytes | 1 | 2009 | 509 | 0.070 |
Why?
|
| Coculture Techniques | 2 | 2023 | 1341 | 0.070 |
Why?
|
| United States | 9 | 2023 | 72317 | 0.070 |
Why?
|
| Membrane Proteins | 2 | 2013 | 7852 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2015 | 1156 | 0.070 |
Why?
|
| Immunocompetence | 2 | 2018 | 138 | 0.070 |
Why?
|
| Inflammation | 2 | 2023 | 10760 | 0.060 |
Why?
|
| Genes, ras | 1 | 2008 | 653 | 0.060 |
Why?
|
| Macrophages | 3 | 2017 | 5768 | 0.060 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1535 | 0.060 |
Why?
|
| Radiography | 3 | 2015 | 6966 | 0.060 |
Why?
|
| Biomimetics | 1 | 2007 | 172 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 4567 | 0.060 |
Why?
|
| Fusobacterium nucleatum | 2 | 2017 | 179 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2013 | 2913 | 0.060 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 4236 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 2012 | 823 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3448 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2012 | 3429 | 0.060 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 2421 | 0.060 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 601 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2013 | 5034 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2019 | 3512 | 0.060 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2006 | 303 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 4355 | 0.060 |
Why?
|
| Hepatocytes | 1 | 2012 | 1232 | 0.060 |
Why?
|
| Antigen Presentation | 3 | 2008 | 1254 | 0.060 |
Why?
|
| Drug Design | 1 | 2010 | 1050 | 0.060 |
Why?
|
| Algorithms | 4 | 2020 | 14025 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2650 | 0.060 |
Why?
|
| Lymphatic Metastasis | 5 | 2015 | 2914 | 0.060 |
Why?
|
| Anastomosis, Surgical | 1 | 2008 | 983 | 0.060 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3793 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 7597 | 0.060 |
Why?
|
| Recurrence | 4 | 2023 | 8470 | 0.060 |
Why?
|
| Ligands | 3 | 2018 | 3271 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2015 | 5247 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 1974 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2019 | 3441 | 0.060 |
Why?
|
| Intention to Treat Analysis | 2 | 2015 | 414 | 0.060 |
Why?
|
| Hospitalization | 1 | 2024 | 10715 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2019 | 800 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 1926 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 2019 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2021 | 54405 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 2060 | 0.050 |
Why?
|
| MART-1 Antigen | 3 | 2011 | 65 | 0.050 |
Why?
|
| Radioimmunotherapy | 1 | 2023 | 91 | 0.050 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 95 | 0.050 |
Why?
|
| Cranial Irradiation | 2 | 2017 | 390 | 0.050 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 1385 | 0.050 |
Why?
|
| Anemia, Aplastic | 1 | 2005 | 230 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 2248 | 0.050 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2003 | 92 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 2 | 2016 | 2891 | 0.050 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 145 | 0.050 |
Why?
|
| Remission Induction | 2 | 2005 | 2395 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4509 | 0.050 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2016 | 598 | 0.050 |
Why?
|
| Cyclosporine | 1 | 2005 | 778 | 0.050 |
Why?
|
| Molecular Sequence Data | 3 | 2012 | 17640 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 1991 | 1669 | 0.050 |
Why?
|
| Azathioprine | 1 | 2023 | 356 | 0.050 |
Why?
|
| Hypopigmentation | 1 | 2002 | 43 | 0.050 |
Why?
|
| Necrosis | 2 | 2003 | 1605 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2010 | 1348 | 0.050 |
Why?
|
| Adoptive Transfer | 2 | 2017 | 819 | 0.050 |
Why?
|
| Tacrolimus | 1 | 2005 | 733 | 0.050 |
Why?
|
| Paclitaxel | 2 | 2015 | 1732 | 0.050 |
Why?
|
| Italy | 2 | 2014 | 841 | 0.050 |
Why?
|
| Receptors, CCR6 | 1 | 2021 | 73 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15835 | 0.050 |
Why?
|
| Peptide Library | 1 | 2002 | 347 | 0.050 |
Why?
|
| Models, Statistical | 2 | 2013 | 5078 | 0.050 |
Why?
|
| Genetic Heterogeneity | 1 | 2024 | 732 | 0.050 |
Why?
|
| Oncogenes | 1 | 2007 | 1223 | 0.050 |
Why?
|
| Immunity | 2 | 2018 | 997 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2017 | 2468 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2020 | 2265 | 0.050 |
Why?
|
| gp100 Melanoma Antigen | 3 | 2006 | 38 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 5363 | 0.050 |
Why?
|
| Nausea | 1 | 2023 | 679 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2021 | 4810 | 0.040 |
Why?
|
| Glioblastoma | 1 | 2015 | 3482 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2024 | 573 | 0.040 |
Why?
|
| Glucocorticoids | 2 | 2022 | 2163 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2021 | 522 | 0.040 |
Why?
|
| Glioma | 1 | 2015 | 3455 | 0.040 |
Why?
|
| Callitrichinae | 2 | 1990 | 20 | 0.040 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2021 | 280 | 0.040 |
Why?
|
| Vaccination | 2 | 2022 | 3381 | 0.040 |
Why?
|
| Freezing | 1 | 2020 | 310 | 0.040 |
Why?
|
| Mice, Congenic | 1 | 2019 | 97 | 0.040 |
Why?
|
| Receptors, CXCR3 | 1 | 2020 | 238 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14409 | 0.040 |
Why?
|
| Radiosurgery | 1 | 2008 | 1342 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2020 | 295 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2217 | 0.040 |
Why?
|
| Interleukin-15 | 2 | 2011 | 185 | 0.040 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2019 | 140 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2016 | 1218 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2013 | 9319 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2012 | 4321 | 0.040 |
Why?
|
| Azetidines | 1 | 2019 | 140 | 0.040 |
Why?
|
| Leukemia, Myeloid | 1 | 2021 | 694 | 0.040 |
Why?
|
| Sirolimus | 1 | 2005 | 1533 | 0.040 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2019 | 178 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 311 | 0.040 |
Why?
|
| Epigenomics | 1 | 2023 | 941 | 0.040 |
Why?
|
| Base Sequence | 1 | 2008 | 12449 | 0.040 |
Why?
|
| Genes, p16 | 1 | 1998 | 159 | 0.040 |
Why?
|
| Filtration | 1 | 2018 | 228 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 1989 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 3027 | 0.040 |
Why?
|
| Multigene Family | 1 | 2020 | 1077 | 0.030 |
Why?
|
| Herpesviridae | 1 | 2017 | 106 | 0.030 |
Why?
|
| Genes, MHC Class I | 2 | 2006 | 240 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2002 | 1229 | 0.030 |
Why?
|
| Galactosylceramides | 1 | 2017 | 92 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2020 | 1693 | 0.030 |
Why?
|
| Peptides | 3 | 2021 | 4342 | 0.030 |
Why?
|
| New Zealand | 1 | 2017 | 357 | 0.030 |
Why?
|
| Time-Lapse Imaging | 1 | 2017 | 194 | 0.030 |
Why?
|
| Obesity | 1 | 2019 | 12934 | 0.030 |
Why?
|
| Neutrophils | 2 | 2020 | 3765 | 0.030 |
Why?
|
| Dendritic Cells | 2 | 2005 | 2746 | 0.030 |
Why?
|
| Odds Ratio | 2 | 2019 | 9639 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 2 | 2016 | 1198 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2022 | 1071 | 0.030 |
Why?
|
| Tissue Embedding | 1 | 2015 | 42 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1998 | 535 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2016 | 2712 | 0.030 |
Why?
|
| Data Mining | 1 | 2021 | 551 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 330 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 6987 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2013 | 732 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 1376 | 0.030 |
Why?
|
| Risk Assessment | 4 | 2021 | 23981 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2021 | 1597 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1998 | 637 | 0.030 |
Why?
|
| Incidence | 3 | 2019 | 21336 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 1612 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2016 | 522 | 0.030 |
Why?
|
| Fibrosis | 1 | 2022 | 2048 | 0.030 |
Why?
|
| Dermatitis | 1 | 2017 | 201 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2015 | 86 | 0.030 |
Why?
|
| Prednisolone | 1 | 2016 | 326 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2021 | 2048 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2017 | 289 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2018 | 559 | 0.030 |
Why?
|
| DNA Helicases | 1 | 2020 | 851 | 0.030 |
Why?
|
| Cell Count | 1 | 2018 | 1835 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1998 | 654 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 2223 | 0.030 |
Why?
|
| Transplantation Immunology | 1 | 2016 | 532 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 678 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2020 | 3097 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2019 | 1008 | 0.030 |
Why?
|
| New England | 1 | 2017 | 1053 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2020 | 3603 | 0.030 |
Why?
|
| Australia | 1 | 2017 | 1246 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 3638 | 0.030 |
Why?
|
| Receptors, Death Domain | 1 | 2013 | 31 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2015 | 320 | 0.030 |
Why?
|
| Smoking | 2 | 2023 | 9051 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 884 | 0.030 |
Why?
|
| Withholding Treatment | 1 | 2017 | 617 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2017 | 1149 | 0.030 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 18234 | 0.030 |
Why?
|
| Monocytes | 1 | 2022 | 2573 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 504 | 0.030 |
Why?
|
| Codon | 1 | 2014 | 602 | 0.030 |
Why?
|
| Acute Disease | 1 | 2023 | 7238 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 726 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1998 | 2382 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2016 | 304 | 0.030 |
Why?
|
| Receptors, Virus | 1 | 2016 | 640 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 715 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 123 | 0.030 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 111 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2008 | 15879 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 2019 | 0.020 |
Why?
|
| Phenotype | 3 | 2021 | 16603 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 1188 | 0.020 |
Why?
|
| Health Behavior | 1 | 2023 | 2641 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2016 | 785 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1704 | 0.020 |
Why?
|
| Lymph Node Excision | 2 | 2009 | 1273 | 0.020 |
Why?
|
| Blood Donors | 1 | 2013 | 345 | 0.020 |
Why?
|
| Genetic Markers | 1 | 1998 | 2612 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 2075 | 0.020 |
Why?
|
| Genes, MHC Class II | 2 | 1989 | 451 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2017 | 1175 | 0.020 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2013 | 331 | 0.020 |
Why?
|
| Aminolevulinic Acid | 1 | 2012 | 144 | 0.020 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2017 | 803 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2018 | 2426 | 0.020 |
Why?
|
| Societies, Medical | 2 | 2013 | 3905 | 0.020 |
Why?
|
| Biological Products | 1 | 2020 | 913 | 0.020 |
Why?
|
| Kidney | 2 | 2016 | 7049 | 0.020 |
Why?
|
| Piperidines | 1 | 2019 | 1657 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14665 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 122 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 176 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 2569 | 0.020 |
Why?
|
| Autophagy | 1 | 2018 | 1321 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 1737 | 0.020 |
Why?
|
| Myeloproliferative Disorders | 1 | 2016 | 613 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 1669 | 0.020 |
Why?
|
| Transplantation, Autologous | 3 | 2003 | 2115 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 4936 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 1809 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2017 | 7954 | 0.020 |
Why?
|
| Interferons | 1 | 2013 | 705 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2020 | 12122 | 0.020 |
Why?
|
| Saguinus | 1 | 1988 | 13 | 0.020 |
Why?
|
| Adenoviridae | 2 | 2003 | 1084 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 3792 | 0.020 |
Why?
|
| Risk Factors | 4 | 2021 | 74152 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 36430 | 0.020 |
Why?
|
| Placebos | 1 | 2013 | 1667 | 0.020 |
Why?
|
| DNA Probes | 1 | 1989 | 544 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 3122 | 0.020 |
Why?
|
| Monkey Diseases | 1 | 1988 | 71 | 0.020 |
Why?
|
| Leukemia | 1 | 2016 | 1523 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 710 | 0.020 |
Why?
|
| Computational Biology | 1 | 2020 | 3512 | 0.020 |
Why?
|
| Universities | 1 | 2013 | 994 | 0.020 |
Why?
|
| Gene Library | 1 | 2010 | 1059 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 591 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1988 | 147 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2012 | 491 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 824 | 0.020 |
Why?
|
| raf Kinases | 1 | 2008 | 118 | 0.020 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2008 | 82 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 1989 | 631 | 0.020 |
Why?
|
| Photosensitizing Agents | 1 | 2012 | 623 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1989 | 719 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 166 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 2423 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 6210 | 0.020 |
Why?
|
| Lung | 2 | 2016 | 9994 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2008 | 277 | 0.020 |
Why?
|
| Epstein-Barr Virus Nuclear Antigens | 1 | 2008 | 157 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 20092 | 0.020 |
Why?
|
| Macaca | 1 | 1988 | 411 | 0.020 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2008 | 256 | 0.020 |
Why?
|
| Genotype | 2 | 2014 | 12982 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 57 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1801 | 0.020 |
Why?
|
| Cell Line | 1 | 2020 | 15599 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 2642 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2009 | 579 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 1991 | 1668 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 652 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 3590 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2008 | 662 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 9534 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 17872 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2010 | 1825 | 0.020 |
Why?
|
| Genetic Engineering | 2 | 2003 | 933 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 1661 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2010 | 1703 | 0.020 |
Why?
|
| K562 Cells | 1 | 2007 | 642 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 5794 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 226 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 1428 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2003 | 1745 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2008 | 21009 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 10551 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2022 | 11531 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2010 | 2625 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2016 | 3469 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 4550 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 617 | 0.010 |
Why?
|
| Skin Diseases | 1 | 2013 | 1092 | 0.010 |
Why?
|
| Health Status | 1 | 2017 | 4075 | 0.010 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 931 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2018 | 4383 | 0.010 |
Why?
|
| Comorbidity | 1 | 2018 | 10498 | 0.010 |
Why?
|
| Survivors | 1 | 2014 | 2370 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 1387 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2008 | 1246 | 0.010 |
Why?
|
| Prostatic Neoplasms | 3 | 2012 | 11116 | 0.010 |
Why?
|
| U937 Cells | 1 | 2003 | 261 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 9605 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 2469 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2008 | 1075 | 0.010 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 1504 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2008 | 1745 | 0.010 |
Why?
|
| Registries | 1 | 2018 | 8223 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 11900 | 0.010 |
Why?
|
| Drug Discovery | 1 | 2009 | 1054 | 0.010 |
Why?
|
| Palliative Care | 1 | 2017 | 3592 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 1990 | 4286 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3687 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 1771 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2003 | 1545 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2019 | 12949 | 0.010 |
Why?
|
| Age Factors | 1 | 2017 | 18401 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2003 | 749 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2008 | 4013 | 0.010 |
Why?
|
| Child | 2 | 2020 | 80156 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 2749 | 0.010 |
Why?
|
| Mucin-1 | 1 | 2003 | 539 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 2180 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 12666 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1989 | 786 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2013 | 12787 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2008 | 2911 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2002 | 1093 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 7439 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 1626 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2002 | 4175 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1991 | 4014 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1988 | 3155 | 0.010 |
Why?
|
| Thiotepa | 1 | 1994 | 66 | 0.010 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 1994 | 98 | 0.010 |
Why?
|
| Genome, Human | 1 | 2007 | 4423 | 0.010 |
Why?
|
| Eosinophils | 1 | 1998 | 947 | 0.010 |
Why?
|
| Physicians | 1 | 1991 | 4591 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2005 | 2527 | 0.010 |
Why?
|
| Genetic Variation | 2 | 2002 | 6571 | 0.010 |
Why?
|
| Boston | 1 | 2005 | 9333 | 0.010 |
Why?
|
| Blood Cells | 1 | 1994 | 304 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1994 | 629 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 6332 | 0.010 |
Why?
|
| Twins, Dizygotic | 1 | 1990 | 236 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1990 | 329 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1058 | 0.010 |
Why?
|
| Chimera | 1 | 1990 | 453 | 0.010 |
Why?
|
| Isoelectric Focusing | 1 | 1988 | 159 | 0.000 |
Why?
|
| Deltaretrovirus Infections | 1 | 1988 | 25 | 0.000 |
Why?
|
| Saimiri | 1 | 1989 | 334 | 0.000 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 2218 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1990 | 2188 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1988 | 815 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1306 | 0.000 |
Why?
|
| Papio | 1 | 1989 | 669 | 0.000 |
Why?
|
| Macaca fascicularis | 1 | 1989 | 903 | 0.000 |
Why?
|
| Major Histocompatibility Complex | 1 | 1990 | 927 | 0.000 |
Why?
|
| Retroviridae | 1 | 1988 | 850 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2002 | 22124 | 0.000 |
Why?
|
| Hematopoiesis | 1 | 1994 | 2049 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 1445 | 0.000 |
Why?
|
| Macaca mulatta | 1 | 1989 | 2332 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1994 | 3396 | 0.000 |
Why?
|
| Alleles | 1 | 1988 | 6909 | 0.000 |
Why?
|
| DNA | 1 | 1990 | 7216 | 0.000 |
Why?
|